As illustrated in Figures 1I, J, a significant decrease in peripheral blood immune repertoire diversity was observed in malignant ovarian tumor patients compared to those with benign tumors (TCR: p = 0.016; BCR: p = 0.0073; Wilcoxon tests). Here, BCR is linked to ovarian cancer.